Stryker (SYK) Stock Forecast & Price Target

$374.43 +3.32 (+0.89%)

Closing price 03:59 PM Eastern

Extended Trading

$374.29 -0.14 (-0.04%)

As of 07:57 PM Eastern

Stryker - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
0

Hold
4

Buy
16

Based on 20 Wall Street analysts who have issued ratings for Stryker in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 4 have given a hold rating, and 16 have given a buy rating for SYK.

Consensus Price Target

$421.90
12.68% Upside

According to the 20 analysts' twelve-month price targets for Stryker, the average price target is $421.90. The highest price target for SYK is $450.00, while the lowest price target for SYK is $370.00. The average price target represents a forecasted upside of 12.68% from the current price of $374.43.

Get the Latest News and Ratings for SYK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Stryker and its competitors.

SYK Analyst Ratings Over Time

Type	Current Forecast 3/24/24 to 3/24/25	1 Month Ago 2/23/24 to 2/22/25	3 Months Ago 12/25/23 to 12/24/24	1 Year Ago 3/25/23 to 3/24/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	16 Buy rating(s)	17 Buy rating(s)	11 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$421.90	$422.15	$405.80	$331.52
Forecasted Upside	12.68% Upside	10.34% Upside	9.44% Upside	-5.98% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Remove Ads

SYK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SYK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Stryker Stock vs. The Competition

Type	Stryker	Medical Companies	S&P 500
Consensus Rating Score	2.80	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	12.25% Upside	21,895.86% Upside	17.15% Upside
News Sentiment Rating	Positive News See Recent SYK News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/21/2025	Needham & Company LLC 2 of 5 stars	Mike Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$442.00 ➝ $442.00	+18.28%
3/4/2025	The Goldman Sachs Group 3 of 5 stars		Set Target		$422.00	+12.41%
2/26/2025	Citigroup 3 of 5 stars	Joanne Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$450.00	+15.22%
2/18/2025	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Turkaly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
2/10/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$418.00 ➝ $443.00	+13.18%
2/3/2025	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$450.00	+17.62%
1/30/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Hold ➝ Hold	$409.00 ➝ $413.00	+5.06%
1/29/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$425.00 ➝ $435.00	+11.57%
1/29/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$427.00 ➝ $435.00	+12.11%
1/29/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$420.00 ➝ $445.00	+12.68%
Get the Latest News and Ratings for SYK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Stryker and its competitors with MarketBeat's FREE daily newsletter.
1/29/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$400.00 ➝ $440.00	+11.41%
1/29/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kyle Rose Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$420.00 ➝ $435.00	+10.15%
12/2/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$370.00 ➝ $445.00	+13.48%
10/30/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$383.00 ➝ $394.00	+8.50%
10/30/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$380.00 ➝ $420.00	+17.04%
10/30/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$366.00 ➝ $370.00	+2.61%
10/30/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$380.00 ➝ $384.00	+6.50%
10/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$378.00 ➝ $405.00	+12.73%
9/10/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$405.00	+11.64%
5/1/2024	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$348.00 ➝ $405.00	+24.47%
4/11/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$365.00 ➝ $400.00	+15.82%
9/5/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$310.00 ➝ $315.00	+10.74%
5/2/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$260.00 ➝ $292.00	-0.78%
5/2/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$320.00 ➝ $345.00	+15.04%
4/23/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$275.00 ➝ $336.00	+10.69%
4/17/2023	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$290.00 ➝ $312.00	+6.94%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 09:55 PM ET.

Should I Buy Stryker Stock? SYK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, March 23, 2025. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com.

Stryker
Bull Case

Here are some ways that investors could benefit from investing in Stryker Co.:

Stryker Co. has a strong market position in the medical technology sector, with a recent stock price of $371.38, indicating solid investor confidence and market performance.
The company has received multiple "buy" ratings from analysts, with a consensus target price of $421.90, suggesting potential for price appreciation.
Recent institutional investments, such as iA Global Asset Management Inc. increasing its holdings by 379.8%, reflect growing confidence among large investors.
Stryker's diverse product offerings in MedSurg, Neurotechnology, and Orthopaedics and Spine segments position it well for growth in various healthcare markets.
The company's payout ratio of 43.30% indicates a commitment to returning value to shareholders through dividends, which can be attractive for income-focused investors.

Stryker
Bear Case

Investors should be bearish about investing in Stryker Co. for these reasons:

Despite positive ratings, the stock has experienced fluctuations, which may indicate volatility and risk for potential investors.
Recent downgrades from some analysts, such as StockNews.com changing its rating from "buy" to "hold," could signal caution regarding future performance.
The competitive landscape in the medical technology industry is intense, with many companies vying for market share, which could impact Stryker's growth prospects.
Economic uncertainties and potential regulatory changes in the healthcare sector may pose risks to Stryker's operations and profitability.
High dependency on innovation and new product development means that any delays or failures in launching new products could adversely affect the company's market position.

SYK Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Stryker is $421.90, with a high forecast of $450.00 and a low forecast of $370.00.
: 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 4 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SYK shares.
: According to analysts, Stryker's stock has a predicted upside of 12.68% based on their 12-month stock forecasts.
: Stryker has been rated by research analysts at Argus, Barclays, Canaccord Genuity Group, Citigroup, JMP Securities, JPMorgan Chase & Co., Needham & Company LLC, Royal Bank of Canada, Stifel Nicolaus, The Goldman Sachs Group, Truist Financial, and Wells Fargo & Company in the past 90 days.
: Analysts like Stryker less than other "medical" companies. The consensus rating score for Stryker is 2.80 while the average consensus rating score for "medical" companies is 2.82. Learn more on how SYK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:SYK) was last updated on 3/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stryker (SYK) Stock Forecast & Price Target